DILEVALOL
- Product Name
- DILEVALOL
- CAS No.
- 75659-07-3
- Chemical Name
- DILEVALOL
- Synonyms
- Levadil;Unicard;Dilevaol;Dilevalon;Sch-19927;DILEVALOL;Dilevalolum;DILEVALOL HCL;(R,R)-Labetalol;Dilevalolum [latin]
- CBNumber
- CB9773028
- Molecular Formula
- C19H24N2O3
- Formula Weight
- 328.41
- MOL File
- 75659-07-3.mol
DILEVALOL Property
- Boiling point:
- 552.7±50.0 °C(Predicted)
- Density
- 1.200±0.06 g/cm3(Predicted)
- pka
- 8.21±0.31(Predicted)
N-Bromosuccinimide Price
- Product number
- FL24822
- Product name
- Dilevalol
- Packaging
- 10mg
- Price
- $145
- Updated
- 2021/12/16
- Product number
- API0019482
- Product name
- 2-HYDROXY-5-((R)-1-HYDROXY-2-(((R)-4-PHENYLBUTAN-2-YL)AMINO)ETHYL)BENZAMIDE
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $498.88
- Updated
- 2021/12/16
- Product number
- FL24822
- Product name
- Dilevalol
- Packaging
- 50mg
- Price
- $507.5
- Updated
- 2021/12/16
- Product number
- API0019482
- Product name
- 2-HYDROXY-5-((R)-1-HYDROXY-2-(((R)-4-PHENYLBUTAN-2-YL)AMINO)ETHYL)BENZAMIDE
- Purity
- 95.00%
- Packaging
- 1G
- Price
- $3104.85
- Updated
- 2021/12/16
- Product number
- CD12036144
- Product name
- 2-Hydroxy-5-((R)-1-hydroxy-2-(((R)-4-phenylbutan-2-yl)amino)ethyl)benzamide
- Purity
- 95+%
- Packaging
- 1g
- Price
- $1583
- Updated
- 2021/12/16
DILEVALOL Chemical Properties,Usage,Production
Description
Dilevalol is a "dual-mechanism" antihypertensive reportedly suitable for a wide range of patients. Its partial beta2-agonist action is expected to induce vasodilation, whereas its beta1-antagonist component may protect against stress-induced hemodynamic charges without altering the cardiac output. Dilevalol is the R,R-isomer of labetalol.
Originator
Schering Plough (USA)
Uses
Specific competitive antagonist at both α-and β-adrenergic receptor sites. Antihypertensive.
Uses
(R,R)-Labetalol is a specific competitive antagonist at both α-and β-adrenergic receptor sites. (R,R)-Labetalol is used as an antihypertensive.
Definition
ChEBI: (R,R)-labetalol is a 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide that has 1R,2R-configuration. It is a conjugate base of a dilevalol(1+).
brand name
Levadil; Dilevalon
World Health Organization (WHO)
Dilevalol, a beta-adrenoreceptor antagonist, was introduced into medicine in 1989 for the treatment of hypertension. Shortly afterwards, its use became associated with isolated cases of hepatic toxicity. Although few cases were reported, the manufacturer discontinued sales in Japan and Portugal, the only countries where the drug was marketed, and withdrew applications for registration elsewhere.